GRK6 Inhibitor Compounds Modulating Signaling Pathways
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hematological malignancies, inflammation diseases, and autoimmune disorders are inadequate in effectively targeting G protein coupled receptor 6 kinase (GRK6) pathways, which are involved in cell proliferation and signaling processes.
Innovation Solution
Development of compounds of Formula I and their pharmaceutically acceptable salts, which act as inhibitors of GRK6 polypeptides, administered to patients or cells to inhibit GRK6 activity, thereby treating hematological malignancies, inflammation diseases, and autoimmune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for hematological malignancies and inflammation diseases, then existing therapeutic approaches are maintained, but effectiveness in targeting GRK6 pathways is inadequate
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of compounds to optimize their inhibitory activity against GRK6. The general formula (I) allows systematic variation of R1, R2, R3, R4, and R5 substituents to tune the compound's potency, selectivity, and pharmacological properties, thereby improving effectiveness in targeting GRK6 pathways while maintaining adaptability across different disease states.
Solution Approach 2:
The patent employs local quality by introducing specific substituent patterns at different positions of the core molecular structure. Different R groups (R1-R5) provide localized functional modifications that enhance binding affinity to GRK6 while preserving the overall molecular framework, enabling targeted inhibition of GRK6 pathways without affecting other kinase pathways.
2Reliability
If GRK6 inhibition is achieved using existing compounds, then some therapeutic effect is obtained, but the compounds lack optimal potency and selectivity
Solution Approach 1:
The patent systematically varies chemical parameters including substituent types, positions, and configurations to optimize both potency and selectivity. The general formula (I) with multiple variable R groups enables fine-tuning of molecular properties to achieve superior GRK6 inhibition compared to existing compounds, while maintaining reliable therapeutic effects in hematological malignancies and inflammation diseases.
Solution Approach 2:
The patent creates optimized copies of existing GRK6 inhibitor scaffolds by retaining the core molecular structure while introducing improved substituent patterns. This approach preserves the proven therapeutic mechanism of action while enhancing potency and selectivity through strategic modifications at key positions of the molecule.
3Reliability
If new GRK6 inhibitor compounds are developed, then improved therapeutic efficacy is achieved, but the complexity of compound synthesis and characterization increases
Solution Approach 1:
The patent segments the molecular structure into distinct functional regions (R1-R5 substituents on a core framework), allowing independent optimization of each region's properties. This modular approach simplifies synthesis by enabling separate preparation of building blocks that can be assembled through standardized coupling reactions, reducing overall complexity despite the enhanced therapeutic efficacy of the final compounds.
Solution Approach 2:
The patent creates a universal scaffold (general formula I) that can accommodate multiple different substituent combinations to target GRK6 in various disease contexts. This multi-functional platform reduces synthesis complexity by using a common core structure and standardized modification protocols, while still achieving improved therapeutic efficacy across different applications.
Data Source
AI summary
This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.